Scott, David L <br/><br/>
New tumour necrosis factor inhibitors for rheumatoid arthritis: are there benefits from extending choice?  [electronic resource] 

 -  Annals of the rheumatic diseases  Jun 2009 
 - 767-9 p.  digital 
<br/><br/> Publication Type: Editorial; Comment 
<br/><br/><label>ISSN: </label>1468-2060 
<br/><br/><label>Standard No.: </label>10.1136/ard.2008.105940  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Anti-Inflammatory Agents--economics<br/>Antibodies, Monoclonal--economics<br/>Antibodies, Monoclonal, Humanized<br/>Arthritis, Rheumatoid--drug therapy<br/>Certolizumab Pegol<br/>Cost-Benefit Analysis<br/>Humans<br/>Immunoglobulin Fab Fragments--economics<br/>Patient Selection<br/>Polyethylene Glycols--economics<br/>Randomized Controlled Trials as Topic<br/>Treatment Outcome<br/>Tumor Necrosis Factor-alpha--antagonists & inhibitors